A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...

A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

Erin Taylor, a disability advocate and botany enthusiast with ALS, used the technology to introduce herself and then welcome ...

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

ALS is a progressive neurodegenerative disease — and there is no cure. Brunner, who was running 3 miles a day at the onset of ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

The Converge platform validated as many as 83% of its treatment targets in disease models, a higher success rate than usual ...

PTC Therapeutics said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of fatal neurodegenerative disease called amyotrophic lateral sclerosis.

PTC Therapeutics will scrap development of its treatment for amyotrophic lateral sclerosis after it failed to meet a primary endpoint in a Phase 2 trial.